Verispan takes a past and future look at drug market

August 24, 2007

Three developments will have a major impact on the pharmaceutical market going forward.

Three developments will have a major impact on the pharmaceutical market going forward. That's the assessment of Tara Hamm, an analyst with market research firm Verispan. Hamm gave an update on the market at Drug Topics' Advanstar headquarters in Woodcliff Lake, N.J., on Aug. 22. The three developments she cited include:

  • potentially significant government influence over health care, with the upcoming Presidential election
  • the growth of e-prescribing
  • the proliferation of retail-based health clinics

Then taking a look back at the market, Hamm told the audience:

  • The average price for generics rose just 5 cents per unit over the past six years. In contrast, branded products rose by an average of 99 cents per unit over the same period.
  • From 2000 to 2007, only 163 new molecular entities (NMEs) were approved, whereas in the seven years before 2000, 232 NMEs received the green light.

 

To see more Hot off the Press news articles, click here.

To go to the Drug Topics homepage, click here.